Beam Therapeutics Inc. Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss
Beam Therapeutics Inc. (BEAM) had Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss of $38.00 thousand as of 2021-03-31, per its 10-Q filed 2021-05-11.
Discontinued › Notes › Debt and Equity Securities › Debt Securities, Held-to-Maturity, Fair Value to Amortized Cost, after Allowance for Credit Loss
us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss · last filed 2021-05-11
- 2021-03-31: Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss $38.00K.
- 2020-12-31: Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss $22.00K.
- 2020-03-31: Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss $353.00K.
| Period end | Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss |
|---|---|
| 2021-03-31 | $38.00K 10-Q · filed 2021-05-11 |
| 2020-12-31 | $22.00K 10-Q · filed 2021-05-11 |
| 2020-03-31 | $353.00K 10-Q · filed 2020-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |